Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;126(1):20-27.
doi: 10.1002/jso.26813.

Cancer risk-reducing surgery: Brazilian Society of Surgical Oncology Guideline Part 2 (Gastrointestinal and thyroid)

Vandré C G Carneiro  1   2   3 , Ana C L V C Gifoni  3 , Benedito M Rossi  4 , Carlos E M da Cunha Andrade  5 , Fernanda T de Lima  6   7 , Henrique de Campos Reis Galvão  8 , Jose C C da Rocha  9 , Leonardo S da Silva Barreto  10 , Patrícia Ashton-Prolla  11 , Rodrigo S C Guindalini  3 , Terence P de Farias  12 , Wesley P Andrade  13   14   15 , Paulo H de Sousa Fernandes  16 , Reitan Ribeiro  17 , Andre Lopes  18 , Audrey T Tsunoda  17   19 , Bruno R B Azevedo  20   21 , Carlos A M Marins  12   22 , Diego N de Albuquerque Oliveira Uchôa  23 , Evandro A S Dos Santos  24 , Felipe J F Coimbra  9 , Francisco A D Filho  25 , Francisco C de Oliveira Lopes  26 , Francisco G Fernandes  27 , Guilherme F Ritt  28 , Gustavo A Laporte  29 , Gustavo C Guimaraes  13 , Heládio Feitosa E Castro Neto  30 , Jocela C Dos Santos  31 , Jordana B de Carvalho Vilela  32 , Jorge G M Junior  29   33 , Juliano R da Cunha  16 , Leonardo M Milhomem  34 , Luciana M da Silva  2 , Luiza de Freitas Maciel  12 , Nathalia M Ramalho  1   3 , Rafael L Nunes  35 , Rodrigo G de Araújo  2 , Rogério de Assunção Ehrhardt  2 , Ronald E D Bocanegra  36 , Tyrone C S Junior  37 , Viviane R de Oliveira  38 , Walyson S Surimã  39 , Miriam de Melo Melquiades  40 , Heber S de Castro Ribeiro  9   41 , Alexandre F Oliveira  42   43
Affiliations

Cancer risk-reducing surgery: Brazilian Society of Surgical Oncology Guideline Part 2 (Gastrointestinal and thyroid)

Vandré C G Carneiro et al. J Surg Oncol. 2022 Jul.

Abstract

Background: Risk-reducing operations are an important part of the management of hereditary predisposition to cancer. In selected cases, they can considerably reduce the morbidity and mortality associated with cancer in this population.

Objectives: The Brazilian Society of Surgical Oncology (BSSO) developed this guideline to establish national benchmarks for cancer risk-reducing operations.

Methods: The guideline was prepared from May to December 2021 by a multidisciplinary team of experts to discuss the surgical management of cancer predisposition syndromes. Eleven questions were defined and assigned to expert groups that reviewed the literature and drafted preliminary recommendations. Following a review by the coordinators and a second review by all participants, the groups made final adjustments, classified the level of evidence, and voted on the recommendations.

Results: For all questions including risk-reducing colectomy, gastrectomy, and thyroidectomy, a major agreement was achieved by the participants, always using accessible alternatives.

Conclusion: This and its accompanying article represent the first guideline in cancer risk reduction surgery developed by the BSSO and it should serve as an important reference for the management of families with cancer predisposition.

Keywords: colon cancer; gastric cancer; practice guideline; surgery; thyroid cancer.

PubMed Disclaimer

References

REFERENCES

    1. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
    1. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
    1. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
    1. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317-327.

LinkOut - more resources